DE60325725D1 - Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs - Google Patents

Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs

Info

Publication number
DE60325725D1
DE60325725D1 DE60325725T DE60325725T DE60325725D1 DE 60325725 D1 DE60325725 D1 DE 60325725D1 DE 60325725 T DE60325725 T DE 60325725T DE 60325725 T DE60325725 T DE 60325725T DE 60325725 D1 DE60325725 D1 DE 60325725D1
Authority
DE
Germany
Prior art keywords
mab
monoclonal antibody
diagnosis
optionally
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325725T
Other languages
German (de)
English (en)
Inventor
Claude Prigent
Anne Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANG BRETAGNE ETS FRANC
Centre National de la Recherche Scientifique CNRS
Francais du Sang Ets
Original Assignee
SANG BRETAGNE ETS FRANC
Centre National de la Recherche Scientifique CNRS
Francais du Sang Ets
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANG BRETAGNE ETS FRANC, Centre National de la Recherche Scientifique CNRS, Francais du Sang Ets filed Critical SANG BRETAGNE ETS FRANC
Application granted granted Critical
Publication of DE60325725D1 publication Critical patent/DE60325725D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
DE60325725T 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs Expired - Lifetime DE60325725D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207212A FR2840905B1 (fr) 2002-06-12 2002-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
PCT/FR2003/001772 WO2003106500A1 (fr) 2002-06-12 2003-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers

Publications (1)

Publication Number Publication Date
DE60325725D1 true DE60325725D1 (de) 2009-02-26

Family

ID=29595167

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325725T Expired - Lifetime DE60325725D1 (de) 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs

Country Status (9)

Country Link
US (1) US7514231B2 (ja)
EP (1) EP1511771B1 (ja)
JP (1) JP4555681B2 (ja)
AT (1) ATE420115T1 (ja)
AU (1) AU2003255671A1 (ja)
CA (1) CA2489214C (ja)
DE (1) DE60325725D1 (ja)
FR (1) FR2840905B1 (ja)
WO (1) WO2003106500A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT868519E (pt) * 1995-12-18 2006-05-31 Sugen Inc Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2

Also Published As

Publication number Publication date
ATE420115T1 (de) 2009-01-15
JP2006513135A (ja) 2006-04-20
WO2003106500A1 (fr) 2003-12-24
US20070117163A1 (en) 2007-05-24
JP4555681B2 (ja) 2010-10-06
AU2003255671A1 (en) 2003-12-31
CA2489214C (fr) 2013-08-06
US7514231B2 (en) 2009-04-07
CA2489214A1 (fr) 2003-12-24
FR2840905B1 (fr) 2006-07-07
FR2840905A1 (fr) 2003-12-19
EP1511771B1 (fr) 2009-01-07
AU2003255671A8 (en) 2003-12-31
EP1511771A1 (fr) 2005-03-09

Similar Documents

Publication Publication Date Title
Li et al. Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype
RU2007139912A (ru) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
ES2569663T3 (es) Procedimiento de diagnóstico
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
WO2005084109A3 (en) Cancer specific gene mh15
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
JP2009525478A5 (ja)
BR0312534A (pt) método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
ATE447715T1 (de) Automatische glykofingerabdruck-strategie
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
WO2016203053A3 (en) Methods of characterising cancer
DE60239059D1 (de) Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums beingen einer antiöstrogen-therapie resistent sind
RU2013113314A (ru) Способы выявления антител против не4 и способы диагностики и/или прогнозирования состояний, ассоциированных с экспрессирующими не4 клетками
DE60126248D1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
ATE331958T1 (de) Verfahren zum nachweis und zur quantifizierung von -aus soliden tumoren abstammenden- zirkulierenden tumorzellen
DE60325725D1 (de) Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
DE60221115D1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
DE50313393D1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
ATE500275T1 (de) Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3
JP2013039111A (ja) スプライシングバリアント

Legal Events

Date Code Title Description
8364 No opposition during term of opposition